Milestone Pharmaceuticals Inc. (MIST) Stock Forecast
MIST analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 7 analysts
- Price target
- $5.86 average of analyst targets
- Upside to target
- +728.4% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.20
- 52-week range
- $0.71 – $2.95
MIST analyst ratings
7 analystsNumber of analysts at each rating.
MIST price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MIST earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.23 | −$0.20 | −$0.12 | −76.7% | 5 |
| Current fiscal year (2026) | −$0.84 | −$0.90 | −$0.77 | −$0.75 | −11.7% | 5 |
| Next fiscal year (2027) | −$0.77 | −$0.96 | −$0.54 | −$0.84 | +7.9% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MIST revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.1M | $800,000 | $2.0M | 0.0% | 7 |
| Current fiscal year (2026) | $3.8M | $2.8M | $6.0M | +147.6% | 7 |
| Next fiscal year (2027) | $22.1M | $11.0M | $34.6M | +476.4% | 7 |
MIST EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MIST revenue: reported and forecast
MIST EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.21 | −$0.21 | −$0.21 | −$0.21 | +1.0% | 2 up · 2 down |
| Current fiscal year (2026) | −$0.97 | −$0.82 | −$0.84 | −$0.84 | −$0.84 | −13.8% | 1 up · 3 down |
| Next fiscal year (2027) | −$1.04 | −$0.78 | −$0.77 | −$0.77 | −$0.77 | −26.1% | 2 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MIST earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MIST beat in 6 of 12.
What analysts expect from MIST
7 analysts cover Milestone Pharmaceuticals; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.86, 728.4% above the latest close of $0.71. Analysts expect earnings of −$0.84 per share for 2026, −11.7% from a year earlier. For 2027 the average estimate is −$0.77 per share on revenue of $22.1 million. Milestone Pharmaceuticals beat the EPS estimate in 6 of the last 12 quarters.
Related: MIST income statement, MIST key metrics, MIST chart. See the MIST stock overview for the latest quote and news.
MIST forecast FAQ
What is Milestone Pharmaceuticals's price target?
The average analyst price target for Milestone Pharmaceuticals is $5.86, 728.4% above the latest close of $0.71.
Is Milestone Pharmaceuticals a buy, hold or sell?
Of 7 analysts covering Milestone Pharmaceuticals, 5 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Milestone Pharmaceuticals's EPS forecast?
Analysts forecast −$0.84 per share for 2026 (range −$0.90 to −$0.77); for 2027 the estimate is −$0.77.
What is Milestone Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $3.8 million, growth of 147.6%; for 2027 it is $22.1 million.
When does Milestone Pharmaceuticals report earnings?
Milestone Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.20.
Does Milestone Pharmaceuticals usually beat earnings estimates?
Milestone Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 12 quarters.